New Research: 2 stocks to buy as Nifty50 heads towards 40,000
Here is the latest financial fact sheet of NOVARTIS. For more details, see the NOVARTIS quarterly results and NOVARTIS share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 1.1 |
No. of shares | m | 24.69 |
1 Week | % | 3.5 |
1 Month | % | 4.6 |
1 Year | % | 85.3 |
52 week H/L | Rs | 1,224.0/559.7 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
NOVARTIS EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 980 | 780 | 770 | 1,099 | 763 | |
Low | Rs | 600 | 420 | 501 | 547 | 554 | |
Sales per share (Unadj.) | Rs | 198.7 | 177.5 | 154.5 | 162.0 | 153.4 | |
Earnings per share (Unadj.) | Rs | 21.0 | 4.1 | 8.5 | -1.5 | 41.9 | |
Diluted earnings per share | Rs | 21.0 | 4.1 | 8.5 | -1.5 | 41.9 | |
Cash flow per share (Unadj.) | Rs | 22.3 | 9.4 | 13.4 | 2.4 | 44.3 | |
Dividends per share (Unadj.) | Rs | 10.00 | 10.00 | 10.00 | 10.00 | 47.50 | |
Adj. dividends per share | Rs | 10.00 | 10.00 | 10.00 | 10.00 | 47.50 | |
Avg Dividend yield | % | 1.3 | 1.7 | 1.6 | 1.2 | 7.2 | |
Book value per share (Unadj.) | Rs | 309.2 | 293.2 | 289.2 | 281.1 | 314.2 | |
Adj. book value per share | Rs | 309.2 | 293.2 | 289.2 | 281.0 | 314.2 | |
Shares outstanding (eoy) | m | 24.69 | 24.69 | 24.69 | 24.69 | 24.69 | |
Price / Sales ratio | x | 4.0 | 3.4 | 4.1 | 5.1 | 4.3 | |
Avg P/E ratio | x | 37.7 | 147.0 | 75.1 | -546.3 | 15.7 | |
P/CF ratio (eoy) | x | 35.5 | 63.8 | 47.5 | 342.7 | 14.9 | |
Price / Book Value ratio | x | 2.6 | 2.0 | 2.2 | 2.9 | 2.1 | |
Dividend payout | % | 47.7 | 244.9 | 118.1 | -663.7 | 113.5 | |
Avg Mkt Cap | Rs m | 19,508 | 14,815 | 15,691 | 20,321 | 16,262 | |
Total wages/salary | Rs m | 1,171 | 1,139 | 1,085 | 1,019 | 356 |
NOVARTIS INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 4,907 | 4,383 | 3,814 | 3,999 | 3,787 | |
Other income | Rs m | 784 | 364 | 342 | 336 | 581 | |
Total revenues | Rs m | 5,691 | 4,747 | 4,155 | 4,334 | 4,369 | |
Gross profit | Rs m | 121 | 117 | 257 | -229 | 651 | |
Depreciation | Rs m | 32 | 131 | 122 | 97 | 61 | |
Interest | Rs m | 16 | 64 | 77 | 48 | 18 | |
Profit before tax | Rs m | 858 | 286 | 400 | -38 | 1,154 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 340 | 186 | 191 | -1 | 120 | |
Profit after tax | Rs m | 518 | 101 | 209 | -37 | 1,034 | |
Gross profit margin | % | 2.5 | 2.7 | 6.7 | -5.7 | 17.2 | |
Effective tax rate | % | 39.6 | 64.8 | 47.8 | 2.6 | 10.4 | |
Net profit margin | % | 10.6 | 2.3 | 5.5 | -0.9 | 27.3 |
NOVARTIS BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 9,887 | 9,973 | 9,224 | 8,259 | 7,861 | |
Current liabilities | Rs m | 3,672 | 4,169 | 3,573 | 3,345 | 2,683 | |
Net working cap to sales | % | 126.7 | 132.4 | 148.2 | 122.9 | 136.7 | |
Current ratio | x | 2.7 | 2.4 | 2.6 | 2.5 | 2.9 | |
Inventory Days | Days | 754 | 136 | 1,161 | 1,059 | 1,201 | |
Debtors Days | Days | 34 | 31 | 37 | 41 | 35 | |
Net fixed assets | Rs m | 10,292 | 2,398 | 12,768 | 11,834 | 12,656 | |
Share capital | Rs m | 123 | 123 | 123 | 123 | 123 | |
"Free" reserves | Rs m | 7,511 | 7,117 | 7,018 | 6,816 | 7,634 | |
Net worth | Rs m | 7,634 | 7,240 | 7,141 | 6,939 | 7,757 | |
Long term debt | Rs m | 0 | 0 | 0 | 0 | 0 | |
Total assets | Rs m | 20,179 | 12,370 | 21,991 | 20,102 | 20,517 | |
Interest coverage | x | 54.9 | 5.5 | 6.2 | 0.2 | 66.9 | |
Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
Sales to assets ratio | x | 0.2 | 0.4 | 0.2 | 0.2 | 0.2 | |
Return on assets | % | 2.6 | 1.3 | 1.3 | 0.1 | 5.1 | |
Return on equity | % | 6.8 | 1.4 | 2.9 | -0.5 | 13.3 | |
Return on capital | % | 11.4 | 4.8 | 6.7 | 0.1 | 15.1 | |
Exports to sales | % | 1.2 | 6.1 | 9.3 | 8.8 | 2.1 | |
Imports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 58 | 269 | 354 | 353 | 80 | |
Imports (cif) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Fx inflow | Rs m | 58 | 269 | 354 | 353 | 80 | |
Fx outflow | Rs m | 1,326 | 1,420 | 974 | 798 | 946 | |
Net fx | Rs m | -1,269 | -1,152 | -621 | -445 | -866 |
NOVARTIS CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | -1,943 | -231 | -692 | 387 | 448 | |
From Investments | Rs m | 2,742 | 559 | 952 | 870 | -1,533 | |
From Financial Activity | Rs m | -298 | -414 | -368 | -356 | -305 | |
Net Cashflow | Rs m | 501 | -86 | -109 | 901 | -1,389 |
Share Holding
Shareholding as on Dec 2023
|
Company Information
|
CHM: C Snook | COMP SEC: Nikhil Malpani | YEAR OF INC: 1947 | BSE CODE: 500672 | FV (Rs): 5 | DIV YIELD (%): 4.6 |
Read: NOVARTIS 2022-23 Annual Report Analysis
More Trading Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES SUN PHARMA CIPLA
Compare NOVARTIS With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES SUN PHARMA CIPLA
Asian markets traded lower, while the US stock indices ended higher overnight with the S&P 500 hitting a record closing high ahead of key economic data.